CLDN18 and adenocarcinoma: The objective of the work was not to duplicate existing international guidelines on testing of HER2, MMR and/or MSI, and PD-L1, but to highlight considerations for the new CLDN18 IHC test, and also provide recommendations for predictive biomarker testing in G/GEJ adenocarcinoma that will optimize testing processes in Canada.